Drug Shortage Report for RAPAFLO

Last updated on 2019-10-26 History
Report ID 93953
Drug Identification Number 02361671
Brand name RAPAFLO
Common or Proper name RAPAFLO 8MG
Company Name ALLERGAN INC
Market Status CANCELLED POST MARKET
Active Ingredient(s) SILODOSIN
Strength(s) 8MG
Dosage form(s) CAPSULE
Route of administration ORAL
Packaging size 90
ATC code G04CA
ATC description DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date 2019-09-23
Actual start date 2019-10-11
Estimated end date 2019-10-28
Actual end date 2019-10-25
Shortage status Resolved
Updated date 2019-10-26
Company comments
Health Canada comments
Tier 3 Status No
Company contact information Company contact information; Telephone number: 800-668-6424 Email address: MR-GENERAL_INQUIRY@allergan.com Website address: allergan.ca Postal address: 500-85 Enterprise Blvd, Markham, Ontario, L6G 0B5

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v1 2019-09-16 English Compare
v2 2019-09-16 French Compare
v3 2019-09-24 English Compare
v4 2019-10-22 English Compare
v5 2019-10-22 French Compare
v6 2019-10-26 English Compare
v7 2019-10-26 French Compare

Showing 1 to 7 of 7